Idioma: Español
Referencias bibliográficas: 17
Paginas: 266-284
Archivo PDF: 423.74 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fisiología respiratoria. En: Enfermedades respiratorias. Temas selectos. España: Elsevier; 2006. p. 29-41.

2. Akella A, et al. Pulmonary surfactants and their role in pathophisiology of lung disorders. Indian J Exp Biol 2013;51(2):5-22.1. Akella A, et al. Pulmonary surfactants and their role in pathophisiology of lung disorders. Indian J Exp Biol 2013;51(2):5-22.

3. Gunst SJ, Zhang W. Actin cytoskeletal dynamics in smooth muscle: a new paradigm for the regulation of smooth muscle contraction. Am J Physiol Cell Physiol 2008;295:C576-C587.

4. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Am Physiol Soc 2003;83:1325-1358.

5. Lontay B, Kiss A, Gergely P, Hartshorne DJ, Erdodi F. Okadaic acid induces phosphorylation and translocation of myosin phosphatase target subunit 1 influencing myosin phosphorylation, stress fiber assembly and cell migration in HepG2 cells. Cell Signal 2005;17:1265-1275.

6. Dippold RP, Fisher SA. Myosin phosphatase isoforms as determinants of smooth muscle contractile function and calcium sensitivity of force production. Microcirculation 2014;21(3):239-248.

7. Khatri JJ, Joyce KM, Brozovich FV, Fisher SA. Role of myosin phosphatase isoforms in cGMP mediated smooth muscle relaxation. J Biol Chem 2001;276:37250-37257.

8. The value of procalcitonin level in community-acquired pneumonia in the ED. Am J Emerg Med 2012;30(7):1248-1254. doi:10.1016/j.ajem.2011.08.009.

9. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011.

10. Procalcitonin in bacterial infections–hype, hope, more or less?

11. A predicition rule to identify low-risk patients with CAP.

12. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adult.

13. Horibe T, Torisawa A, Kohno M, Kawakami K. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide. BMC Cancer.

14. Srivastava P, Shafiq N, Bhasin DK, et al. Differential expression of heat shock protein (HSP) 70-2 gene polymorphism in benign and malignant pancreatic disorders and its relationship with disease severity and complications. JOP 2012;3(4):414-419.

15. Han FF, Li L, Shang BY, Shao RG, Zhen YS. Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair. Asian Pac J Cancer Prev 2014;5(17):7043-7048.

16. Oi T, Onozawa Y, Fuse N, et al. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;4(3):629-636.

17. Slotta-Huspenina J, Becker KF, Feith M, Walch A, Langer R. Heat Shock Protein 90 (HSP90) and Her2 in adenocarcinomas of the esophagus. Cancers (Basel) 2014;6(3):1382-1393.